While eczema and psoriasis are both chronic inflammatory skin conditions characterized by red, itchy rashes, they differ significantly in their biological origins and clinical presentation. Eczema (atopic dermatitis) is primarily a barrier defect often linked to a genetic deficiency in the protein filaggrin, which leads to hypersensitivity and moisture loss [1]. In contrast, psoriasis is a chronic autoimmune condition driven by an overactive immune system that accelerates the life cycle of skin cells, causing them to build up rapidly on the surface [2].
Visually, these conditions occupy different 'territories' on the body and exhibit distinct textures. Eczema typically appears in the creases of the elbows or behind the knees, presenting as intensely itchy, weeping, or crusty patches with ill-defined borders [3]. Psoriasis tends to favour the extensor surfaces like the outer elbows and knees, presenting as thick, well-demarcated silvery scales (plaques) on a deep red base [4]. Furthermore, while eczema is often associated with intense pruritus (itching) that leads to scratching and secondary infection, psoriasis is frequently described as a stinging or burning sensation [1][2].
From a molecular perspective, the cytokines involved in these conditions differentiate their inflammatory pathways. Eczema is predominantly driven by a Th2-mediated immune response, involving interleukin-4 (IL-4) and IL-13, which further compromises the skin's lipid barrier [1]. Psoriasis is characterised by a Th17/Th1 pathway, where the overproduction of IL-17 and TNF-alpha triggers rapid keratinocyte proliferation, shortening the cell turnover cycle from 28 days to just 3 to 5 days [4].
In the Australian climate, environmental triggers play a crucial role in managing both conditions. High UV levels can often improve psoriasis symptoms—a concept utilised in clinical phototherapy, whereas heat and perspiration can exacerbate eczema symptoms (sudamen) and lead to increased irritation and flare-ups [3]. Accurate diagnosis by a dermatologist is essential, as the specialised moisturisers and topical steroids prescribed for a barrier defect may differ from the systemic biologics or keratolytic agents required for autoimmune plaque management.
For those managing the delicate nature of a compromised barrier, our Surface Calm was formulated with a blend of ceramides and cholesterol to ensure cleansing remains a supportive rather than stripping process. To further encourage a resilient complexion, many of our customers find that Balance Biome Crème provides the necessary microbiome support and soothing hydration required to stabilise and protect sensitised skin.
FAQ
Can you have both eczema and psoriasis at the same time?
Yes, although it is rare, a condition known as 'dermatitis psoriasiformis' or 'psoriasiform dermatitis' occurs when a patient exhibits overlapping clinical features of both conditions [5]. Because they are governed by different immune pathways (Th2 vs Th17), having both simultaneously requires a highly personalised treatment plan to address both barrier repair and immune regulation [2].
How do triggers differ between these two conditions?
Eczema triggers are often external allergens or irritants such as harsh soaps, wool, dust mites, or changes in humidity that stress the skin barrier [1]. Psoriasis triggers are more frequently systemic, including emotional stress, physical injury to the skin (the Koebner phenomenon), infections like strep throat, or certain medications [4].
What are the most effective moisturising ingredients for Australian eczema sufferers?
Australian guidelines emphasise the use of 'bland' emollients. Ingredients like ceramides, cholesterol, and fatty acids are vital to repair the lipid bilayer [1]. Humectants like glycerine are preferred over urea in acute stages of eczema because urea can sting broken skin, whereas urea is often preferred in psoriasis to help dissolve thick scales [3][5].
References:
[1] Langan SM, et al. Atopic dermatitis. The Lancet. 2020;396(10247):345-360. doi:10.1016/S0140-6736(20)31286-1
[2] Armstrong AW, Read C. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. JAMA. 2020;323(19):1945-1960. doi:10.1001/jama.2020.4006
[3] Australasian College of Dermatologists. Eczema (Atopic Dermatitis) Position Statement. 2022. Available at: www.dermcoll.edu.au
[4] Boehncke WH, Schön MP. Psoriasis. The Lancet. 2015;386(9997):983-94. doi:10.1016/S0140-6736(14)61909-7
[5] Guttman-Yassky E, et al. Loosening the knots: The role of Th2 and Th17 pathways in skin inflammation. Journal of Allergy and Clinical Immunology. 2018;141(5):1542-1553. doi:10.1016/j.jaci.2018.03.003
Medical Disclaimer: This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any new skincare regimen. Content reviewed by a biomedical scientist.
